KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash from Investing Activities (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Cash from Investing Activities data on record, last reported at $26.0 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 55.31% year-over-year to $26.0 million; the TTM value through Dec 2025 reached $115.4 million, down 6.9%, while the annual FY2025 figure was $115.4 million, 6.9% down from the prior year.
  • Cash from Investing Activities reached $26.0 million in Q4 2025 per PACB's latest filing, up from $18.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $242.3 million in Q3 2023 and bottomed at -$460.8 million in Q2 2021.
  • Average Cash from Investing Activities over 5 years is -$15.9 million, with a median of $24.2 million recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: crashed 16017.8% in 2021, then soared 414.72% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at $65.8 million in 2021, then grew by 22.28% to $80.4 million in 2022, then crashed by 182.8% to -$66.6 million in 2023, then soared by 187.48% to $58.2 million in 2024, then tumbled by 55.31% to $26.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $26.0 million in Q4 2025, $18.9 million in Q3 2025, and $25.3 million in Q2 2025.